Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Nurix Therapeutics Inc (NASDAQ: NRIX) was $24.07 for the day, down -4.48% from the previous closing price of $25.20. In other words, the price has decreased by -$4.48 from its previous closing price. On the day, 0.76 million shares were traded. NRIX stock price reached its highest trading level at $25.41 during the session, while it also had its lowest trading level at $23.9601.
Ratios:
Our analysis of NRIX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.28 and its Current Ratio is at 5.28. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $35.
On October 11, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $41.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 30 ’24 when van Houte Hans sold 2,368 shares for $24.30 per share. The transaction valued at 57,554 led to the insider holds 37,270 shares of the business.
Hansen Gwenn sold 3,437 shares of NRIX for $83,536 on Oct 30 ’24. The Chief Scientific Officer now owns 50,670 shares after completing the transaction at $24.30 per share. On Oct 30 ’24, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 4,182 shares for $24.30 each. As a result, the insider received 101,644 and left with 28,084 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1785074560 and an Enterprise Value of 1284120320. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.22 while its Price-to-Book (P/B) ratio in mrq is 4.28. Its current Enterprise Value per Revenue stands at 22.758 whereas that against EBITDA is -6.889.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $27.60, while it has fallen to a 52-week low of $4.38. The 50-Day Moving Average of the stock is -0.35%, while the 200-Day Moving Average is calculated to be 36.84%.
Shares Statistics:
NRIX traded an average of 677.69K shares per day over the past three months and 750390 shares per day over the past ten days. A total of 70.84M shares are outstanding, with a floating share count of 69.65M. Insiders hold about 1.67% of the company’s shares, while institutions hold 92.00% stake in the company. Shares short for NRIX as of 1728950400 were 9240563 with a Short Ratio of 13.64, compared to 1726185600 on 9364663. Therefore, it implies a Short% of Shares Outstanding of 9240563 and a Short% of Float of 14.000000000000002.
